Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…
Sponsor: NRG Oncology
NCT ID: NCT07166406
Sites in Minnesota: - Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Essentia Health Saint Mary's Medical Center — Duluth, Minnesota
- Miller-Dwan Hospital — Duluth, Minnesota
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in Minnesota: - Research Site — Rochester, Minnesota
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2, Phase 3 Recruiting Industry
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT06109272
Sites in Minnesota: - Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041 — Saint Louis Park, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Minnesota: - Research Site 121 — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Minnesota: - M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Minnesota: - University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Network
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…
Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in Minnesota: - University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Minnesota: - M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unr…
Sponsor: Academic and Community Cancer Research United
NCT ID: NCT05168163
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
Sponsor: RayzeBio, Inc.
NCT ID: NCT06726161
Sites in Minnesota: - Research Facility — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…
Sponsor: GI Innovation, Inc.
NCT ID: NCT05824975
Sites in Minnesota: - Mayo Clinic in Minnesota — Rochester, Minnesota
Phase 2 Recruiting Industry
Safety Run-in Cohort (cohort 1): 10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days. Monotherapy Cohorts (Cohort 2 and 3) Cohort 2 (HCC) This part is a single-agent, single one-dos…
Sponsor: Virogin Biotech Canada Ltd
NCT ID: NCT05223816
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Academic/Other
This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (with bevacizumab and atezolizumab or druvalumab) in treating patients liver canc…
Sponsor: Mayo Clinic
NCT ID: NCT03942328
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1. to learn about the safety and tolerability of H…
Sponsor: HepaRegeniX GmbH
NCT ID: NCT06638502
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Minnesota: - Exelixis Clinical Site #68 — Rochester, Minnesota
Phase 1 Recruiting Industry
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT…
Sponsor: Alnylam Pharmaceuticals
NCT ID: NCT06600321
Sites in Minnesota: - Clinical Trial Site — Rochester, Minnesota
Phase 1 Recruiting Industry
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated incl…
Sponsor: TORL Biotherapeutics, LLC
NCT ID: NCT06005740
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
This is an open-label phase 1 study with an escalation part and an expansion part.
Sponsor: Abbisko Therapeutics Co, Ltd
NCT ID: NCT04906434
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Minnesota: - Massive Bio SYNERGY-AI site — Duluth, Minnesota
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health-St. Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Duluth Clinic — Duluth, Minnesota
- St. Luke's Hospital of Duluth — Duluth, Minnesota
- Lake Region Healthcare — Fergus Falls, Minnesota
Phase 4 Recruiting Academic/Other
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection…
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT06084234
Sites in Minnesota: - Hennepin Healthcare — Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota
NA Recruiting Academic/Other
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable primary live…
Sponsor: Maastricht University
NCT ID: NCT06914648
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Recruiting Academic/Other
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Sponsor: Mayo Clinic
NCT ID: NCT06349642
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Recruiting Academic/Other
This observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can create ways to improve resilience during recovery. The main questions it aims t…
Sponsor: Mayo Clinic
NCT ID: NCT06674811
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota